C4 Therapeutics (CCCC) Receivables (2019 - 2026)

C4 Therapeutics' Receivables history runs 8 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Receivables fell 64.09% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 64.09% YoY), while the FY2025 annual figure was $2.4 million, down 22.6% from the prior year.
• Receivables was $2.9 million for Q1 2026 at C4 Therapeutics, up from $2.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $13.6 million in Q1 2024 to a low of $500000.0 in Q3 2023.
• Historically, Receivables has averaged $4.1 million across 5 years, with a median of $2.2 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Receivables slumped 74.23% in 2022, then soared 2475.57% in 2024.
• A 5-year view of Receivables shows it stood at $1.5 million in 2022, then soared by 701.02% to $11.8 million in 2023, then sank by 73.71% to $3.1 million in 2024, then retreated by 22.6% to $2.4 million in 2025, then grew by 20.07% to $2.9 million in 2026.
• The last three Receivables figures came in at $2.9 million (Q1 2026), $2.4 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.